Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Sculpher

Showing results (121-130 of 174) with videos related to

Pageof 18
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 11, 2009
Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force reportMichael Drummond, Marco Barbieri, John Cook, et al.
Heart (British Cardiac Society)|July 15, 2016
Cost-effectiveness of implantable cardiac devices in patients with systolic heart failureStuart Mealing, Beth Woods, Neil Hawkins, et al.
Heart (British Cardiac Society)|December 1, 2006
Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA studyAndrew Briggs, Borislava Mihaylova, Mark Sculpher, et al.
Plos One|May 3, 2019
Adherence to the iDSI reference case among published cost-per-DALY averted studiesJoanna Emerson, Ari Panzer, Joshua T Cohen, et al.
Trials|May 6, 2020
The HOME Study: Statistical and economic analysis plan for a randomised controlled trial comparing the addition of Proactive Psychological Medicine to usual care, with usual care alone, on the  time spent in hospital by older acute hospital inpatientsNicholas Magill, Ian R White, Jane Walker, et al.
International Journal of Cardiology|April 13, 2005
Management of non-ST-elevation acute coronary syndromes: how cost-effective are glycoprotein IIb/IIIA antagonists in the UK National Health Service?Stephen Palmer, Mark Sculpher, Zoe Philips, et al.
Plos One|March 8, 2017
Cost-effectiveness of adjunct non-pharmacological interventions for osteoarthritis of the kneeBeth Woods, Andrea Manca, Helen Weatherly, et al.
Pharmacoeconomics|November 29, 2021
Developing the EQ-5D-5L Value Set for Uganda Using the 'Lite' ProtocolFan Yang, Kenneth R Katumba, Bram Roudijk, et al.
BMJ (Clinical Research Ed.)|September 29, 2016
Cancer Drugs Fund requires further reformRichard Grieve, Keith Abrams, Karl Claxton, et al.
Health Policy and Planning|August 21, 2023
Economic evaluation of self-help group interventions for health in LMICs: a scoping reviewJessica Ochalek, Naomi K Gibbs, Rita Faria, et al.
Pageof 18

Showing results (121-130 of 174) with videos related to

Sort By:
Pageof 18
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 11, 2009
Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force reportMichael Drummond, Marco Barbieri, John Cook, et al.
Heart (British Cardiac Society)|July 15, 2016
Cost-effectiveness of implantable cardiac devices in patients with systolic heart failureStuart Mealing, Beth Woods, Neil Hawkins, et al.
Heart (British Cardiac Society)|December 1, 2006
Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA studyAndrew Briggs, Borislava Mihaylova, Mark Sculpher, et al.
Plos One|May 3, 2019
Adherence to the iDSI reference case among published cost-per-DALY averted studiesJoanna Emerson, Ari Panzer, Joshua T Cohen, et al.
Trials|May 6, 2020
The HOME Study: Statistical and economic analysis plan for a randomised controlled trial comparing the addition of Proactive Psychological Medicine to usual care, with usual care alone, on the  time spent in hospital by older acute hospital inpatientsNicholas Magill, Ian R White, Jane Walker, et al.
International Journal of Cardiology|April 13, 2005
Management of non-ST-elevation acute coronary syndromes: how cost-effective are glycoprotein IIb/IIIA antagonists in the UK National Health Service?Stephen Palmer, Mark Sculpher, Zoe Philips, et al.
Plos One|March 8, 2017
Cost-effectiveness of adjunct non-pharmacological interventions for osteoarthritis of the kneeBeth Woods, Andrea Manca, Helen Weatherly, et al.
Pharmacoeconomics|November 29, 2021
Developing the EQ-5D-5L Value Set for Uganda Using the 'Lite' ProtocolFan Yang, Kenneth R Katumba, Bram Roudijk, et al.
BMJ (Clinical Research Ed.)|September 29, 2016
Cancer Drugs Fund requires further reformRichard Grieve, Keith Abrams, Karl Claxton, et al.
Health Policy and Planning|August 21, 2023
Economic evaluation of self-help group interventions for health in LMICs: a scoping reviewJessica Ochalek, Naomi K Gibbs, Rita Faria, et al.
Pageof 18